CG Oncology logo
CG Oncology
CGON | NASDAQ
Chart Builder DCF Calculator
$84.78
+$10.38 (+13.95%)
At close: Nov 16, 2026, 4:00 PM ET
$83.89
-$0.89 (-1.04%)
After-hours: Nov 16, 2026, 7:48 PM ET

CG Oncology Company Profile

Company profile explained

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Key Executives

Name Position
Arthur Kuan President, Chairman & CEO
James DeTore Chief Financial Officer
Amy Steele Vice President of Finance & Administration
Bing Kung Vice President of Corporate Development
Joshua F. Patterson General Counsel, Chief Compliance Officer & Secretary
Sarah Connors Vice President of Communications & Patient Advocacy
Swapnil Bhargava Chief Technical Officer
Vijay Kasturi Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 19, 2026 4 Filing
Oct 19, 2026 4 Filing
Oct 19, 2026 3 Filing
Sep 17, 2026 4 Filing
Aug 18, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
View All SEC Filings ➞
CG Oncology
CG Oncology logo
Country United States
IPO Date Jan 25, 2024
Industry Biotechnology
Sector Healthcare
Employees 142
CEO Arthur Kuan

Contact Details

3000 Pegasus Park Drive Dallas, Texas 75247 United States

Stock Details

Ticker Symbol CGON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001991792
CUSIP Number 156944100
ISIN Number US1569441009
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.